[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focal-seizure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focal-seizure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,65,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643647","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-100643647",false,"NCT07594119","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","FOCUS 2","Inclusion Criteria:\n\n1. Age 18 - 75\n2. BMI 18-45 kg\u002Fm2\n3. Diagnosis of focal epilepsy for ≥24 months prior to Visit 1\n4. Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis\n5. Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs\n6. Ability to keep accurate daily focal seizure records using an e-diary\n\nExclusion Criteria:\n\n1. Known hypersensitivity or prior exposure to RAP-219.\n2. Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur\n3. Anticipated need for surgery during the study period\n4. Medical history of any of the following:\n\n   1. generalized epilepsy\n   2. focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type\n   3. psychogenic nonepileptic seizure (PNES)\n   4. status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56).\n   5. epilepsy surgery within 12 months prior to Visit 1 (Day -56).\n5. Participation in another clinical study of an investigational product within 12 weeks or 5 half-lives of this other investigational product","ALL","18 Years","75 Years",{"count":21,"type":22},312,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.",[28,29,30],"Focal Seizure","Epilepsy","Focal Epilepsy",[32,33],"Focal Preserved Consciousness","Focal Impaired Consciousness","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":22},"2026-06",{"date":42,"type":22},"2029-09",{"name":44,"class":45},"Rapport Therapeutics Inc.","INDUSTRY",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":14,"acronym":52,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":26,"conditions":56,"keywords":57,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":64,"locationsCount":46},"100636299","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-focus-1-100636299","NCT07563881","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1","FOCUS 1",{"count":54,"type":22},333,[25],[28,29,30],[32,33],"2026-06-12",{"date":60,"type":38},"2026-06-16",{"date":62,"type":38},"2026-06-05",{"date":42,"type":22},{"name":44,"class":45},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100609809","phase-2-a-long-term-study-of-the-safety-and-effectiveness-of-rap-219-in-adults-with-focal-onset-seizures-100609809","NCT07219407","A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures","An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures","Inclusion Criteria:\n\n* Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.\n* Diagnosis of refractory focal epilepsy\n* Stable RNS(c) system settings\n* A demonstrated history of compliance with RNS(c) system data interrogation and upload\n* Good overall health other than focal epilepsy, per Investigator.\n* BMI ≥ 18 kg\u002Fm\\^2 and ≤ 45 kg\u002Fm\\^2\n* Willing and able to adhere to all aspects of the protocol.\n\nExclusion Criteria:\n\n* Known of hypersensitivity to RAP-219\n* Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator\n* Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods","70 Years",{"count":74,"type":22},30,[76],"PHASE2","This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.",[30,29,79,80,28,81],"Refractory Focal Epilepsy","Seizure","Focal Onset Seizure",[83,29,84,85],"Focal Seizures","RNS","Long episode","2026-01-22",{"date":88,"type":38},"2026-01-23",{"date":90,"type":38},"2025-12-15",{"date":92,"type":22},"2028-02-03",{"name":44,"class":45},7,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":100,"conditions":106,"keywords":107,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100592935","phase-2-double-blind-randomized-trial-of-prax-628-in-adults-with-focal-seizures-to-evaluate-efficacy-and-safety-power1-100592935","NCT06999902","Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)","A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)","POWER1","Inclusion Criteria:\n\n1. A diagnosis of focal onset epilepsy according to the International League Against Epilepsy (ILAE) Classification of Epilepsy.\n2. Past evidence by computed tomography (CT) or magnetic resonance imaging (MRI) that has ruled out a progressive cause of epilepsy in the judgement of the investigator and\u002For in consultation with the medical monitor.\n\nExclusion Criteria:\n\n1. Subject has had any of the of the following within the 12-month period preceding trial entry: History of pseudo or psychogenic seizures, cluster seizures where the individual seizures cannot be counted, an episode of convulsive status epilepticus requiring hospitalization and intubation, or subject only has focal seizures with awareness that do not have motor activity.\n2. Planned epilepsy surgery during the course of the clinical trial.\n3. History of neurosurgery for seizures \\\u003C1 year prior to enrollment, or radiosurgery \\\u003C2 years prior to enrollment or vagus nerve stimulation (VNS) implantation.\n4. History of schizophrenia, obsessive-compulsive disorder, or other serious mental health disorders.\n5. History of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded.\n6. History of cardiac disease(s)\u002Fcardiac conduction disorders\u002For cardiac structural abnormality(ies).\n7. Has a positive test result or a known history of a positive test result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibody at Screening.\n8. Is pregnant or is breastfeeding at the time of Screening or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose.\n9. Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene therapy.",{"count":104,"type":22},230,[76,25],[28],[28],"2025-05-23",{"date":110,"type":38},"2025-05-31",{"date":112,"type":38},"2024-12-11",{"date":114,"type":22},"2025-12-08",{"name":116,"class":45},"Praxis Precision Medicines",26]